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Impaired rate-dependent depression (RDD) of the Hoffman
reflex is associated with reduced dorsal spinal cord potas-
sium chloride cotransporter expression and impaired spinal
g-aminobutyric acid type A receptor function, indicative of
spinal inhibitory dysfunction. We have investigated the path-
ogenesis of impaired RDD in diabetic rodents exhibiting fea-
tures of painful neuropathy and the translational potential of
this marker of spinal inhibitory dysfunction in human painful
diabetic neuropathy. Impaired RDD and allodynia were pre-
sent in type 1 and type 2 diabetic rats but not in ratswith type
1 diabetes receiving insulin supplementation that did not re-
store normoglycemia. Impaired RDD in diabetic rats was
rapidly normalized by spinal delivery of duloxetine acting
via 5-hydroxytryptamine type 2A receptors and temporally
coincident with the alleviation of allodynia. Deficits in RDD
and corneal nerve density were demonstrated in patients
with painful diabetic neuropathy compared with healthy con-
trol subjects and patients with painless diabetic neuropathy.
Spinal inhibitory dysfunction and peripheral small fiber pa-
thology may contribute to the clinical phenotype in painful
diabetic neuropathy. Deficits in RDD may help identify pa-
tientswith spinallymediated painful diabetic neuropathywho
may respond optimally to therapies such as duloxetine.
Approximately 30% of patients with diabetes develop
painful neuropathy (1). The efficacy of current therapies
is highly variable (2,3), potentially reflecting diverse pain
generator sites (4,5) and etiological mechanisms (6) in
patients with diabetes with neuropathic pain. Phenotyp-
ing patients based on their symptom complex and puta-
tive mechanisms may enable more accurate prediction of
treatment response (7). Although standard neurophysiol-
ogy and quantitative sensory testing can differentiate pa-
tients with diabetes with and without neuropathy (8),
recent Initiative on Methods, Measurement, and Pain As-
sessment in Clinical Trials (IMMPACT) recommendations
have emphasized a need for more detailed phenotyping of
patients with painful neuropathy in order to improve
both clinical care and success rates for putative analgesic
drugs in clinical trials (9).
Rate-dependent depression (RDD), a measure of
change in amplitude of the Hoffman (H) reflex over
consecutive stimulations, can be recorded from electro-
myograms during standard electrophysiological proce-
dures. RDD is impaired after disinhibition of spinal
sensory processing caused by spinal cord injury in both
awake humans (10,11) and anesthetized animals (12,13).
In rats, RDD is driven by g-aminobutyric acid (GABA)
acting though GABA type A (GABAA) receptors and is
attenuated when GABAA receptor–mediated inhibitory
function is disrupted (14). We recently demonstrated
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that loss of RDD separated rats demonstrating impaired
spinal GABAergic inhibitory function from rats with normal
spinal GABAergic function, despite both showing a similar
neuropathic pain phenotype (15). Measuring RDD may
therefore allow assessment of the relative contribution
of spinal inhibitory dysfunction and segregation of periph-
erally from spinally generated pain. While it is becoming
apparent that only a minor fraction of patients with di-
abetes who experience pain exhibit the “irritable nocicep-
tor” phenotype (5), it is not known whether RDD, and by
implication spinal inhibitory systems, are impaired in any
or all patients with painful diabetic neuropathy.
We investigated the pathogenic basis of RDD attenuation
in diabetic rats and determined that modulation of RDD
predicts the therapeutic efficacy of duloxetine, which
alleviates neuropathic pain by enhancing spinal inhibitory
systems (16,17). We also translated our experimental
findings by assessing whether RDD and small-fiber pa-
thology could segregate patients with painful compared
with painless diabetic neuropathy.
RESEARCH DESIGN AND METHODS
Animals and Induction of Diabetes
Studies were performed using adult female Sprague-Dawley
or adult male Zucker Diabetic Fatty (ZDF) rats. Rats were
housed two to three per cage with free access to food
(Harlan 5001 diet) and water and maintained in an
American Association for the Accreditation of Laboratory
Animal Care–approved vivarium. Studies were performed
according to protocols approved by the Institutional Animal
Care and Use Committee of the University of California, San
Diego. Insulin-deficient diabetes was induced after an over-
night fast by injection of 50 mg/kg i.p. streptozotocin (STZ)
(Sigma-Aldrich, St. Louis, MO), freshly dissolved in 0.9%
sterile saline. Hyperglycemia was confirmed using a glucose
meter (OneTouch Ultra; LifeScan, Milpitas, CA) from blood
obtained by tail prick 4 days after STZ injection, and blood
and cerebrospinal fluid were collected at study conclusion.
Neuropathy
Peripheral nerve function was assessed by measuring
sciatic motor and sensory nerve conduction velocity and
paw thermal and tactile response thresholds as previously
described in detail (18).
RDD of the H-Reflex
Under isoflurane anesthesia, one hind limb was secured
and a transcutaneous needle electrode inserted at the ankle
for tibial nerve stimulation. Two recording electrodes were
inserted into hind paw interosseous muscles. Stimulus
generation and recording of M and H waves from the
resulting electromyogram were performed using a Power-
lab 4/30 connected to a computer running Scope software
(AD Instruments, Colorado Springs, CO). Tibial nerve
stimulation used bursts of 5 3 200 ms duration square
waves with 40-ms interpulse intervals. Each burst was re-
peated at 1 Hz stimulation frequency, which, in normal rats,
causes an ;40% decrease in H-wave amplitude between the
first and subsequent bursts (15). Stimulation intensity
was increased by 0.125-V increments until the stimulus
that produced the maximum H-wave amplitude (Hmax)
was found. RDD was calculated as percentage change in
H-wave amplitude evoked by the second (H2) compared
with the first (H1) stimulation burst. In rats, H2 is rep-
resentative of all subsequent responses (14).
Pharmacological Interventions
3-O-methyl-glucose (3-OMG) (Sigma-Aldrich) was injected
at 5 mmol/kg i.p. 1–2 min before STZ administration. Dose
and timing were chosen to prevent hyperglycemia despite
systemic presence of STZ (19). Continuous insulin treat-
ment to prevent prolonged hyperglycemia was initiated in
STZ-injected rats immediately after onset of hyperglycemia
by subdermal implantation of insulin pellets that release
2 IU/24 h (Linshin Canada Inc.). Blood glucose levels were
assessed weekly and additional pellets supplemented as
necessary. The effects of short-term insulin treatment
were assessed by implanting one subcutaneous insulin pel-
let or providing twice-daily subcutaneous insulin injections
(4 IU, Humulin; Eli Lilly, Indianapolis, IN) to diabetic rats
that were otherwise untreated for the previous 8 weeks.
Blood glucose was assessed daily in the insulin pellet group
and at 30-min intervals after acute insulin injection.
The 5-hydroxytryptamine type 2A/C (5-HT2A/C) receptor
agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
hydrochloride (DOI) (20 mg; Sigma-Aldrich) was dissolved
in water. Cymbalta (Eli Lilly, Indianapolis, IN) was used as
a source of duloxetine hydrochloride (20 mg) and dissolved
in saline. The 5-HT2A/1D receptor antagonist ketanserin
(20 mg; Sigma-Aldrich) and selective 5-HT2A receptor antag-
onist pruvanserin (EMD 281014, provided by G. Bartoszyk,
Merck KGaA, Darmstadt, Germany) were dissolved in sa-
line. Drug formulations and doses were selected from pre-
vious studies (17).
Western Blotting
Spinal cords were obtained by hydraulic extrusion after
decapitation of anesthetized rats. The lumbar enlargement
was dissected on ice into dorsal and ventral portions that
were collected into ice-cold homogenization buffer (50 mmol/L
Tris-HCl, pH 7.4; 150 mmol/L NaCl; 1 mmol/L EDTA;
0.5% Triton X; and protease inhibitor cocktail) and homo-
genized before centrifugation (14,000g). Protein (7–15 mg)
was prepared by incubation for 30 min in Laemmli sample
buffer at 37°C before separation on 4–12% SDS-PAGE
Bis-Tris gels (Novex; Invitrogen, Carlsbad, CA) and im-
munoblotted on nitrocellulose. Membranes were incu-
bated with KCC2 (1:2,000; Millipore) and actin (1:2,000;
Sigma-Aldrich) antibodies. Quantification of immuno-
reactivity was performed by densitometric analysis.
For each animal, band intensities were normalized by
calculating the ratio of intensity of the band of interest
to the intensity of the actin (loading control) band. Nor-
malized data were expressed as a percentage of group
mean of values obtained for nondiabetic rats run on the
same gel.
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Human Studies
Studies were approved by National Research Ethics Service
Committee North West–Greater Manchester (09/H1006/38).
All participants provided written informed consent. Study
conduct adhered to the tenets of the declaration of Helsinki.
Twenty-seven patients with type 1 diabetes and 15 age-
matched control subjects were recruited. Participants
underwent the following assessments: Neuropathy Disability
Score (NDS), Neuropathy Symptom Profile (NSP), vibration
perception threshold (VPT), and thermal perception thresh-
olds; sural sensory amplitude (SSamp) and conduction velocity
(SSCV); and peroneal motor amplitude (PMamp) and conduc-
tion velocity (PMCV). For intraepidermal nerve fiber density
(IENFD) assessment, 3-mm punch skin biopsy specimens
Table 1—Indices of diabetes and neuropathy at death in rat models of type 1 (STZ) and type 2 (ZDF) diabetes
N
Body
weight
(g)
Blood
glucose
(mmol/L)
Blood
HbA1c
(%)
CSF
glucose
(mmol/L)
Sciatic
MNCV
(m/s)
Sciatic
SNCV
(m/s)
Thermal
latency
(s)
Tactile
threshold
(g)
Control 9 279 6 3*** 5.4 6 0.1*** 4.3 6 0.1*** 2.7 6 0.2*** 54.6 6 1.2*** 58.3 6 1.6*** 8.3 6 0.4* 15.0***
STZ 10 201 6 4 27.4 6 2.1 7.6 6 0.2 17.1 6 1.5 45.6 6 0.9 47.9 6 1.8 10.8 6 0.8 3.1
STZ + 3-OMG 7 274 6 3*** 6.3 6 0.3*** 4.3 6 0.1*** nd 54.3 6 0.8*** 55.2 6 1.5* 7.6 6 0.4*** 15.0***
STZ + insulin 6 259 6 7*** 11.9 6 4.9** 4.2 6 0.3*** 4.9 6 1.4*** 48.2 6 1.0 55.7 6 2.5* 8.1 6 0.8* 15.0***
Lean 12 429 6 4* 9.0 6 0.3*** nd nd 56.2 6 0.9* 57.4 6 2.3* 7.1 6 0.5** 10.8**
ZDF 9 380 6 19 29.0 6 1.1 nd nd 53.7 6 0.5 50.7 6 1.9 9.9 6 1.0 3.4
Parametric data are group mean 6 SEM with statistical analysis by unpaired t test or one-way ANOVA with Dunnett post hoc test.
Nonparametric data are group median with Mann-Whitney U test or Kruskal-Wallis with Dunn post hoc test. CSF, cerebrospinal fluid;
MNCV, motor nerve conduction velocity; nd, not determined; SNCV, sensory nerve conduction velocity. *P , 0.05, **P , 0.01, and
***P , 0.001 vs. STZ or ZDF as appropriate.
Figure 1—Fifty percent paw withdrawal threshold (A) and RDD measured as H2-to-H1 amplitude ratio (B) in controls, STZ diabetic (STZ)
rats, STZ + 3-OMG rats, and STZ diabetic rats treated with insulin (STZ + Insulin) after 8 weeks of diabetes. For A, data are presented as
group median 6 interquartile range. **P < 0.01, *P < 0.05 compared with STZ by the Kruskal-Wallis test followed by the Dunn multiple
comparisons test. For B, data are presented as group mean 6 SEM. **P < 0.01, *P < 0.05 compared with STZ by one-way ANOVA
followed by the Tukey post hoc test. C and D: Upper panel shows Western blots of KCC2 and actin protein in lumbar dorsal (C) or ventral
(D) spinal cord of control (C), STZ diabetic (STZ), and insulin-treated STZ diabetic (STZ+I) rats. Lower panel shows KCC2 intensity
normalized to actin loading control. Data are presented as mean 6 SEM, with N = 5 animals/group, and pooled from three independently
run Western blots. *P < 0.05 by one-way ANOVA followed by the Tukey post hoc test.
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were obtained from the dorsum of the foot and a bright-
field immunohistochemistry protocol was used according
to published guidelines (20). Linear IENFD (number of
fibers/mm) was established in at least four sections of
50-mm thickness according to published counting rules
(21). Corneal nerve fiber density (CNFD), nerve branch
density (CNBD), and nerve fiber length (CNFL) were quan-
tified according to established techniques (22).
A modified Toronto Diabetic Neuropathy Expert Group (8)
recommendation was followed to define neuropathy, incorpo-
rating small-fiber neuropathy measures (2 SDs outside nor-
mal range for CNFD or IENFD) if PMCV was normal. Patients
were stratified into painful (visual analog score [VAS] .3 of
10) (n = 13) and painless (VAS #3 of 10) (n = 14) groups.
For H-reflex studies, a standardized protocol was adopted
in which participants sat comfortably in a quiet room
semirecumbent at 45° and facing forward with eyes open.
Monophasic 1-ms duration square wave pulses were deliv-
ered using surface silver-silver chloride electrodes to the
tibial nerve in the popliteal fossa (11). Surface 9-mm diam-
eter silver-silver chloride recording electrodes were placed on
the long axis of the soleus. Peak-peak Hmax was determined
by incrementing stimulation current by 1 mA at 0.3 Hz.
Only patients with an Hmax of .400 mV were included,
with five patients excluded because of absent or low voltage
waveforms—four without and one with a pain VAS .3. For
RDD, trains of three stimuli were delivered at 0.3, 0.5, 1, 3,
and 5 Hz. Stimulation order was randomized with a mini-
mum of 10 s allowed between each run. Submaximal stim-
ulation producing an H-reflex 50–75% of Hmax was used.
Consecutive H-reflex recordings within trains were termed
H1–H3, respectively. RDD, defined as H3-to-H1 amplitude
ratio, was calculated for each stimulation frequency (11), as
H2 did not identify the maximal change from H1 (A.G.M.,
unpublished observations).
Statistics
Statistical analyses were performed with Prism statistical
software (GraphPad Software, Inc., La Jolla, CA). Parametric
data were analyzed using unpaired two-tailed t test, one-way
ANOVA followed by Tukey or Dunnett post hoc test for
multiple comparisons, or two-way ANOVA followed by
Bonferroni post hoc test as indicated. Nonparametric
data were analyzed using the Kruskal-Wallis test followed
by Dunn post hoc test for multiple comparisons as indi-
cated. Pairwise comparisons were made using the Mann-
Whitney U test (post hoc Bonferroni-corrected P , 0.05).
Correlations were performed using Spearman rank test and
expressed as a coefficient (r) with significance level.
RESULTS
3-OMG or Insulin Treatment Prevents Impaired RDD
and Indices of Painful Neuropathy After STZ
Administration
STZ-injected rats showed weight loss, hyperglycemia, increased
HbA1c, and elevated cerebrospinal fluid glucose at the end of
the study (Table 1). Continuous insulin therapy and 3-OMG
pretreatment, to impede pancreatic b-cell STZ uptake and
subsequent apoptosis (23), both prevented all systemic phys-
iological consequences of STZ injection. STZ diabetic rats
showed expected indices of loss-of-function neuropathy such
as slowing of nerve conduction velocity and thermal hypoal-
gesia (Table 1) while concurrently exhibiting tactile allodynia
and impaired RDD (Fig. 1A–B). Pretreatment with 3-OMG or
prolonged insulin treatment prevented all manifestations of
neuropathy. STZ diabetes also caused a selective reduction of
spinal KCC2 protein expression in the dorsal (P , 0.05 vs.
control) (Fig. 1C), but not ventral (Fig. 1D), horn that was
prevented by insulin supplementation.
Short-term Insulin Treatment Reverses Impaired
RDD in Diabetic Rats
STZ diabetic rats that were untreated for 8 weeks sub-
sequently received either a subcutaneous insulin pellet
releasing 2 IU insulin/day or 4 IU insulin injected at 12-h
intervals. Diabetic rats that received an insulin pellet did
not show a significant reduction in blood glucose levels
until the 4th day after implantation (Fig. 2A), and values
Figure 2—Blood glucose values after implantation of an insulin pellet (A) or after a single subcutaneous injection of 4 IU insulin (B) in
otherwise untreated STZ diabetic rats. Data are group mean6 SEM of N = 6/group. *P< 0.05, **P< 0.01, ***P< 0.001 compared with time
0 by repeated-measures ANOVA followed by the Dunnett post hoc test. C: RDD measured in these two groups of diabetic rats and in
untreated diabetic rats (untreated) 4 days after initiation of insulin therapy and 12 h after the last insulin injection. Data are group mean 6
SEM of N = 6/group. *P < 0.05 vs. untreated diabetic rats by one-way ANOVA followed by the Dunnett post hoc test.
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remained higher than in controls (Table 1). In contrast,
insulin acutely reduced blood glucose within 2 h, although
animals remained hyperglycemic (Fig. 2B). The effect of in-
sulin resolved within 3.5 h so that rats receiving insulin
injections were exposed to two short periods of diminished
hyperglycemia per day. RDD, measured on day 4 after ini-
tiation of both treatment regimes, and 12 h after the last
insulin injection, was significantly improved in both insulin
treatment groups (P , 0.05) (Fig. 2C) compared with un-
treated diabetic rats and was equivalent to that of control
animals (Fig. 1B). Loss of RDD can be reversed by short-
term insulin replacement, which dissociates correction of
RDD deficits from immediate restoration of normoglycemia.
RDD Is Impaired in Experimental Type 2 Diabetes
ZDF rats, a model of type 2 diabetes, developed hyper-
glycemia (20.2 6 2.2 mmol/L) by 8 weeks of age that
persisted until the end of the study and was accompanied
by indices of neuropathy that matched those of STZ di-
abetic rats (Table 1). RDD was not significantly different
from lean control rats at 8 weeks of age but was signifi-
cantly impaired at 20 and 32 weeks (P, 0.05), paralleling
onset of tactile allodynia (Supplementary Fig. 1).
Duloxetine and DOI Restore RDD in Diabetic Rats in a
5-HT2A Receptor–Dependent Fashion
Tactile allodynia in STZ diabetic rats is reversed by the
serotonin-norepinephrin reuptake inhibitor duloxetine
and the 5-HT2A/C receptor agonist DOI in a 5-HT2A
receptor–dependent fashion (17). We investigated whether
the antiallodynic effects of these agents could be predicted
by their effects on RDD deficits. STZ diabetic rats had
significantly impaired RDD compared with controls (P ,
0.001) (Fig. 3A). Intrathecal administration of either dulox-
etine (20 mg) or DOI (20 mg) significantly (P , 0.05) re-
stored RDD within 5 min of administration with similar
relative efficacy and in agreement with the previously re-
ported magnitude of effect on tactile allodynia (17).
The 5-HT2A/D receptor antagonist ketanserin (20 mg in-
trathecal [IT]) or 5-HT2A receptor antagonist pruvanserin
(20 mg IT), administered 5 min after duloxetine or DOI, re-
versed the restoration of RDD within 10 min, whereas this
persisted in vehicle-treated animals (Fig. 3B), confirming that
5-HT2A receptor activation mediated the restoration of RDD.
Patients With Painful Diabetic Neuropathy Have
Impaired RDD
To explore the translational potential of these findings,
we investigated RDD in subjects with type 1 diabetes and
painful or painless diabetic neuropathy and healthy
control subjects. Clinical characteristics are summarized
in Table 2. Diabetes duration and HbA1c were comparable
between patients with painful and painless neuropathy.
Of the 13 patients with painful diabetic neuropathy, two
took duloxetine, one pregabalin, one gabapentin, one am-
itriptyline, and one duloxetine and pregabalin in combi-
nation (Fig. 5A). Both the NSP (P , 0.0001) and NDS
(P , 0.01) were significantly higher in patients with
diabetes, irrespective of pain status, compared with con-
trol subjects. NSP was significantly higher in patients with
diabetes with painful compared with painless neuropathy.
Patients with diabetes with painful and painless diabetic
neuropathy had a reduction in PMCV (P , 0.0001), SSCV
(P , 0.0001), PMamp (P , 0.0001), and SSamp (P ,
0.01) and increased VPT (P , 0.001) and cold (P ,
0.01) and warm (P , 0.01) perception thresholds com-
pared with control subjects. Structural measures of small-
fiber neuropathy including IENFD (P , 0.01), CNFD (P ,
0.0001), CNBD (P , 0.001), and CNFL (P , 0.001) were
significantly reduced in both groups of patients with di-
abetes. CNFD was significantly lower in patients with
painful compared with painless diabetic neuropathy
(P , 0.05), but there was no significant difference for
other small- or large-fiber parameters.
Figure 3—RDD in control (C) and STZ diabetic (D) rats measured
5 min after IT delivery of vehicle (Veh), 20 mg duloxetine (Dulox), or
20 mg DOI (A) or the above followed 5 min later by either ketanserin
(Ket) or pruvanserin (Pruv) also at 20 mg (B). Data are group
mean + SEM of N = 6–8/group. *P < 0.05, ***P < 0.001 vs. in-
dicated group by one-way ANOVA followed by the Tukey post
hoc test.
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Representative H-reflex waveforms collected at 1-Hz
stimulation in subjects with and without painful neurop-
athy are presented in Fig. 4A. RDD increased progressively
in all groups with increasing stimulation frequency but was
significantly attenuated in patients with painful diabetic
neuropathy compared with control subjects at frequencies
of 0.5 Hz (P , 0.05), 1 Hz (P , 0.001), 3 Hz (P , 0.05),
and 5.0 Hz (P , 0.05) (Fig. 4B) and at 1 Hz in patients
with painful compared with those with painless diabetic
neuropathy (P , 0.01). The magnitude of RDD in indi-
vidual patients with painful diabetic neuropathy showed
considerable variance (Fig. 5A), but there was a significant
correlation between RDD and VAS score at 1 Hz (rs =
0.688; P = 0.01). RDD magnitude at 1 and 3 Hz signifi-
cantly correlated with NSP but showed no significant cor-
relation with physiological or structural measures of
small- or large-fiber neuropathy (Table 3).
Patients With Painful Diabetic Neuropathy Have
Corneal Nerve Loss
CNFD was reduced in patients with diabetes both painless
(P, 0.05) and painful (P, 0.001) diabetic neuropathy com-
pared with control subjects and further reduced in patients
with painful compared with painless diabetic neuropathy
(P, 0.05) (Table 2 and Fig. 5B). Measures of corneal inner-
vation showed no significant correlation with pain VAS
within the painful neuropathy group (CNFD, rs= 20.134,
NS; CNFL, rs = 20.370, NS; CNBD, rs = 20.217, NS)
although across the diabetic neuropathy cohort pain VAS
showed a significant negative correlation with CNFD
(rs =20.567; P = 0.004) and CNFL (rs =20.404; P = 0.04).
DISCUSSION
We previously reported loss of RDD in a rat model of type 1
diabetes (14) and identified the contribution of spinal dis-
inhibition to neuropathic pain states (15). The present pre-
clinical studies show that RDD deficits in STZ-injected rats
are not due to STZ neurotoxicity. Firstly, RDD deficits did
not occur in STZ-injected rats pretreated with 3-OMG, a
nontoxic, nonmetabolizable glucose derivative that pro-
tects pancreatic b-cells from destruction by STZ (23). Sec-
ondly, impaired RDD was absent in STZ-injected rats given
extended insulin treatment from the onset of hyperglyce-
mia. Thirdly, RDD deficits also developed in the ZDF rat
model of type 2 diabetes. As both models of diabetes mir-
rored the neuropathy phenotype of many patients with di-
abetes by exhibiting concurrent conduction slowing and
thermal hypoalgesia, these findings strengthen the potential
clinical relevance of RDD as a biomarker for spinal disinhi-
bition in patients with either type 1 or type 2 diabetes.
The efficacy of extended insulin replacement in pre-
venting RDD deficits in STZ diabetic rats cannot distin-
guish between hypoinsulinemia or hyperglycemia as the
primary pathogenic mechanism. We therefore compared
treatment using a subcutaneous insulin pellet to generate
Table 2—Demographic, clinical, and neuropathy variables in control subjects and patients with and without painful diabetic
neuropathy
Control subjects
(n = 15)
Painful diabetic neuropathy
(n = 13)
Painless diabetic neuropathy
(n = 14)
Age (years) 48 6 16 57 6 12 52 6 17
Duration of diabetes (years) N/A 32 6 16 26 6 19
HbA1c (%) 5.5 6 0.4 7.9 6 0.9*** 9.1 6 1.9***
NDS (0–10) 0.1 6 0.2 3.3 6 1.5** 3.1 6 1.4**
NSP (0–38) 0.1 6 0.2 6.6 6 3.5***++ 2.4 6 2.1*
VPT (V) 5.7 6 5.7 18.3 6 13*** 16.8 6 11.4***
Cold perception threshold (°C) 28.8 6 2.0 23.4 6 5.3** 26.1 6 3.5**
Warm perception threshold (°C) 37.2 6 2.5 42.3 6 4.0** 40.6 6 4.0*
SSamp (mV) 18.7 6 9.6 6.6 6 4.6** 10.8 6 7.7**
SSCV (m/s) 51.7 6 3.1 40.6 6 7.9*** 42.2 6 6.2***
PMamp (mV) 5.9 6 2.0 1.9 6 1.2*** 2.8 6 2.3**
PMCV (m/s) 49.9 6 4.4 37.8 6 6.9*** 38.9 6 8.4***
H-reflex latency (ms) 32.4 6 3.9 37.1 6 3.7** 36.1 6 3.3*
H-reflex amplitude (mV) 2,024.7 6 596.0 959.2 6 927.3 1,071.4 6 957.9
IENFD (no./mm) 10.6 6 4.0 4.2 6 1.5* 4.9 6 3.1**
CNFD (no./mm2) 33.7 6 8.6 16.6 6 8.0***+ 24.7 6 7.4*
CNFL (mm/mm2) 25.6 6 6.3 13.6 6 6.2*** 18.1 6 5.5**
CNBD (no./mm2) 91.3 6 41.4 35.6 6 1.4*** 47.4 6 26.7**
Results are expressed as mean 6 SD. N/A, not applicable. Statistically significant differences identified with the Kruskal-Wallis test
followed by Dunn post hoc test for multiple comparisons: *P , 0.05, **P , 0.01, and ***P, 0.001 for control subjects against diabetic
neuropathy groups; +P , 0.05 and ++P , 0.01 for painful diabetic neuropathy against painless diabetic neuropathy.
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a continuous mild reduction of hyperglycemia with insulin
injections that produced acute and transient reductions of
hyperglycemia. Both regimens resulted in restoration of
RDD, disassociating impaired RDD from ambient hyper-
glycemia. There is increasing awareness that insulin has
direct effects on the nervous system. Insulin receptors are
present in primary sensory neurons and at nociceptor
termination sites in the spinal cord dorsal horn (24,25).
In diabetic rodents, local insulin administration to the
periphery (26,27) or spinal cord (28) ameliorated indices
of neuropathy and neuropathic pain (29) without impacting
systemic hyperglycemia. Systemically delivered insulin
also crosses the blood-brain barrier to activate central
nervous system insulin receptors (30). The trophic effect
of insulin extends to patients with diabetes, as continuous
subcutaneous insulin infusion improved corneal nerve
density without altering HbA1c (31). The onset of im-
paired RDD in ZDF rats, a model of type 2 diabetes, could
potentially argue against a pathogenic role of insulin defi-
ciency per se. However, RDD appeared only at an age where
both insulinopenia and insulin resistance are features of the
model (32,33). Insulin resistance has also been reported in
peripheral nerves of type 2 diabetic rodents (34). As the
time course of impaired RDD coincided with that of tactile
allodynia, impaired RDD appears to be a biomarker of neu-
ropathic pain in models of both type 1 and type 2 diabetes.
For further testing of the association between RDD
and neuropathic pain, the effects of the 5-HT2A/C receptor
agonist DOI and the serotonin-norepinephrine reuptake
inhibitor duloxetine were evaluated in relation to RDD in
diabetic rats. Both agents alleviate neuropathic pain in
diabetic rats in a 5-HT2A/C–dependent fashion (17), and
reversal of its effects on RDD by ketanserin and pruvan-
serin indicate actions mediated through 5-HT2A–binding
sites. Duloxetine is recommended for painful diabetic
neuropathy but has moderate overall efficacy and good
effect in only a subgroup of patients (2). Interestingly,
patients with diabetes with painful neuropathy and less
efficient conditioned pain modulation, suggestive of spi-
nal disinhibition, show greater therapeutic responses to
duloxetine (35). The rapid restoration of allodynia and
RDD by both drugs suggests that RDD could be useful
for identification of therapies that selectively target neu-
ropathic pain arising from spinal disinhibition and allows
identification of patients most likely to respond to ther-
apies targeting this axis.
The pertinence of our preclinical studies to humans is
supported by observations that RDD is conserved across
species, including humans (36,37). Indeed, the H-reflex in
normal anesthetized rats shows a frequency dependence
that is remarkably similar in magnitude to that observed
in awake humans (15,38,39), while deficits caused in rats
by the metabolic injury of diabetes are notably similar to
those seen in anesthetized rats and awake humans after
physical spinal cord injury (10,11,13,15,38). To test the
potential for clinical translation of RDD as a biomarker
for the pain generator site, we compared RDD in patients
with painful and painless diabetic neuropathy with that of
control subjects. While initial H-wave amplitude was
reduced in both groups of patients with diabetes, RDD
was impaired only in patients with painful diabetic neu-
ropathy. This impairment was unrelated to the severity
of neuropathy, as there was no significant correlation be-
tween RDD and measures of large- or small-fiber dysfunc-
tion. However, patients with higher pain scores had
greater RDD attenuation, suggesting that spinal inhibi-
tory dysfunction coexists with, and may contribute to,
the pain phenotype in a subgroup of subjects with painful
diabetic neuropathy.
Figure 4—Tibial H-reflex RDD is attenuated in patients with pain-
ful diabetic neuropathy. A: Representative electromyogram
traces showing M and H waves in response to three consecutive
stimulations at 1-Hz frequency in a patient with painless (upper
triplicate) and painful (lower triplicate) diabetic neuropathy. Note
the decline of the H-wave amplitude in the traces from the pa-
tient with painless neuropathy that illustrates RDD. B: RDD,
expressed as H3-to-H1 ratio, at ascending stimulation frequen-
cies in control subjects (n = 15: filled gray circles, solid line) and
patients with painless (n = 14: open circles, large dashed line)
and painful (n = 13: filled black circles, small dashed line) dia-
betic neuropathy. Data are group mean 6 SEM. Statistically sig-
nificant differences were identified with the Kruskal-Wallis test
followed by Dunn post hoc test for multiple comparisons: *P <
0.05, ***P < 0.001 for painful diabetic neuropathy against control
group; ++P < 0.01 for painful diabetic neuropathy against pain-
less diabetic neuropathy.
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Although RDD directly measures muscle depolarization
in response to motor output from the spinal cord, it is
modulated by spinal inhibitory systems (12,14) and there-
fore can provide information about spinal processing of
sensory inputs. Use of other electrophysiological testing
paradigms, such as evaluation of the nociceptive flexion
reflex, a nociceptor-specific reflex elicited in response to
stimulation of Ad and C fibers, could provide additional
information about how spinal processing is altered during
painful diabetic neuropathy. Indeed, a recent study sug-
gests that painful diabetic neuropathy is associated with
enhanced nociceptive flexion reflex (40), but it is unclear
whether this is due to increased peripheral sensitivity or
altered spinal reflex processing. Future studies should
address whether an enhanced nociceptive flexion reflex
is associated with impaired RDD or an independent
phenomenon.
Several of the patients with painful neuropathy were
already taking the antineuropathic pain medications
duloxetine, pregabalin, or amitriptyline, and we could
not therefore undertake a systematic quantification of their
effects on clinical pain and RDD. However, three of
four patients with the most impaired RDD were taking
duloxetine, whereas patients on amitriptyline or pregabalin
tended to have RDD values within the range observed in
patients with painless diabetic neuropathy and control
subjects. Both amitriptyline and duloxetine increase sero-
tonin and norepinephrine levels, which enhance descend-
ing inhibition (41). However, amitriptyline also inhibits
5-HT2A receptors (42) and therefore may not be able to
reverse spinal disinhibition due to impaired GABAA re-
ceptor–mediated inhibition arising from decreased spinal
KCC2 (43). We speculate that patients with impaired RDD
indicative of impaired spinal inhibition may find duloxe-
tine to be an efficacious treatment for their neuropathic
pain. Further studies investigating the predictive value of
RDD for the response to neuropathic pain treatment with
specific agents will be important to test the premise that
therapeutic responses may be significantly improved by
accurately phenotyping patients and tailoring therapy
that is mechanistically appropriate. A parallel approach
focusing on peripherally driven pain has been tested in
two randomized placebo controlled studies in which the
best response to treatment with oxcarbazepine (44) and
lignocaine 5% patch (45) was achieved in patients with an
irritable nociceptor phenotype and preserved small-fiber
function. Ultimately a battery of tests designed to identify
peripheral and central pain generator sites may be opti-
mal to identify therapy for achieving optimal efficacy.
In addition to RDD impairment, patients with diabetes
with painful neuropathy also had a significant reduction
in CNFD, confirming our previous findings (46) and in
keeping with accruing data showing greater small-fiber
pathology (47,48) and autonomic deficits (49) in patients
with painful diabetic neuropathy. However, there was no
significant correlation between corneal innervation and
RDD status, suggesting that these pathologies may be
independent of each other. This raises the intriguing pos-
sibility that these distinct biomarkers could be used to-
gether to refine our understanding of the underlying
pathophysiology of pain in individual patients.
The present discovery study represents a first attempt
to translate RDD analysis from experimental animals to
patients with diabetes with neuropathic pain, albeit in a
cross-sectional study with a relatively small sample size.
There is clearly a need for larger cross-sectional and longi-
tudinal studies to define the normative range for RDD in
humans and to develop criteria to define abnormal RDD
that can be applied to individual subjects for phenotyping
purposes. Some patients with severe neuropathy have un-
obtainable tibial H-reflexes, potentially limiting the utility
of RDD to those with mild to moderate neuropathy.
Nevertheless, impaired RDD and a reduction in CNFD could
together provide a means to more accurately phenotype
Figure 5—Tibial H-reflex RDD exhibits variability in patients with painful diabetic neuropathy but does show a relationship with pain VAS. A:
Individual values for RDD at 1-Hz stimulation in control subjects (filled gray circles) and patients with painless (open circles) or painful (filled
black/colored circles) diabetic neuropathy. Antineuropathic pain medication is indicated by letters adjacent to the relevant data point. A,
amitriptyline; D, duloxetine; G, gabapentin; P, pregabalin. B: Dot plots of individual values for CNFD in control subjects and patients with
painless or painful diabetic neuropathy.
diabetes.diabetesjournals.org Marshall and Associates 1387
patients with painful diabetic neuropathy. Such phenotyp-
ing could allow a more stratified approach to designing
clinical trials of drugs in subjects with painful diabetic
neuropathy and ultimately a more personalized therapeutic
approach, based on site of pain generation and mechanism
of drug action.
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NSP 0.111 0.193 0.431 0.395 0.307
Significance NS NS 0.028 0.049 NS
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